Development of a reliable assay to measure glypican-1 in plasma and serum reveals circulating glypican-1 as a novel prostate cancer biomarker

SUPPLEMENTARY MATERIALS



Supplementary Figure 1: Transcriptional dysregulation in CaP. Box-and-whisker plots (5th-95th percentile) of gene expression in non-cancerous prostate tissue (control, n = 52), primary prostate tumor tissue with 60-79% positively stained cancer nuclei (60-79% CaP, n = 286), and primary prostate tumor tissue with 80-100% positively stained cancer nuclei (80-100% CaP, n = 226). Normalized RNA-Seq expression data (UQ-FPKM) was downloaded from the NCI Genomic Data Commons data portal (https://portal.gdc.cancer.gov/, Data Release 4.0).